Last reviewed · How we verify
SBI-100 Ophthalmic Emulsion, 1.0% — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
SBI-100 Ophthalmic Emulsion, 1.0% (SBI-100 Ophthalmic Emulsion, 1.0%) — Skye Bioscience, Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| SBI-100 Ophthalmic Emulsion, 1.0% TARGET | SBI-100 Ophthalmic Emulsion, 1.0% | Skye Bioscience, Inc. | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- SBI-100 Ophthalmic Emulsion, 1.0% CI watch — RSS
- SBI-100 Ophthalmic Emulsion, 1.0% CI watch — Atom
- SBI-100 Ophthalmic Emulsion, 1.0% CI watch — JSON
- SBI-100 Ophthalmic Emulsion, 1.0% alone — RSS
Cite this brief
Drug Landscape (2026). SBI-100 Ophthalmic Emulsion, 1.0% — Competitive Intelligence Brief. https://druglandscape.com/ci/sbi-100-ophthalmic-emulsion-1-0. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab